These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30655185)

  • 41. The impact of interrupting enzyme replacement therapy in late-onset Pompe disease.
    Wenninger S; Gutschmidt K; Wirner C; Einvag K; Montagnese F; Schoser B
    J Neurol; 2021 Aug; 268(8):2943-2950. PubMed ID: 33625582
    [TBL] [Abstract][Full Text] [Related]  

  • 42. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population.
    Musumeci O; la Marca G; Spada M; Mondello S; Danesino C; Comi GP; Pegoraro E; Antonini G; Marrosu G; Liguori R; Morandi L; Moggio M; Massa R; Ravaglia S; Di Muzio A; Filosto M; Tonin P; Di Iorio G; Servidei S; Siciliano G; Angelini C; Mongini T; Toscano A;
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):5-11. PubMed ID: 25783438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy.
    van der Meijden JC; Kruijshaar ME; Harlaar L; Rizopoulos D; van der Beek NAME; van der Ploeg AT
    J Inherit Metab Dis; 2018 Nov; 41(6):1205-1214. PubMed ID: 29556838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022.
    Lefeuvre C; De Antonio M; Bouhour F; Tard C; Salort-Campana E; Lagrange E; Behin A; Sole G; Noury JB; Sacconi S; Magot A; Nadaj-Pakleza A; Lacour A; Beltran S; Spinazzi M; Cintas P; Renard D; Michaud M; Bedat-Millet AL; Prigent H; Taouagh N; Arrassi A; Hamroun D; Attarian S; Laforêt P;
    Neurology; 2023 Aug; 101(9):e966-e977. PubMed ID: 37419682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry.
    Lessard LER; Tard C; Salort-Campana E; Sacconi S; Béhin A; Bassez G; Orlikowski D; Merle P; Nollet S; Gallay L; Bérard F; Robinson P; Bouhour F; Laforêt P
    Mol Genet Metab; 2023 Jul; 139(3):107611. PubMed ID: 37285781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum.
    Kronn DF; Day-Salvatore D; Hwu WL; Jones SA; Nakamura K; Okuyama T; Swoboda KJ; Kishnani PS;
    Pediatrics; 2017 Jul; 140(Suppl 1):S24-S45. PubMed ID: 29162675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease.
    Alandy-Dy J; Wencel M; Hall K; Simon J; Chen Y; Valenti E; Yang J; Bali D; Lakatos A; Goyal N; Mozaffar T; Kimonis V
    Ann Transl Med; 2019 Jul; 7(13):276. PubMed ID: 31392188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Late-onset pompe disease in Iran: A clinical and genetic report.
    Nazari F; Sinaei F; Nilipour Y; Fatehi F; Streubel B; Ashrafi MR; Aryani O; Nafissi S
    Muscle Nerve; 2017 Jun; 55(6):835-840. PubMed ID: 27649523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toward deconstructing the phenotype of late-onset Pompe disease.
    Schüller A; Wenninger S; Strigl-Pill N; Schoser B
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):80-8. PubMed ID: 22253010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [GAA gene variants and genotype-phenotype correlations in patients with glycogen storage disease type Ⅱ].
    Huang YL; Sheng HY; Jia XF; Su XY; Zhao XY; Xie T; Tang CF; Liu SC; Li XZ; Zhang W; Mei HF; Zeng CH; Liu L
    Zhonghua Er Ke Za Zhi; 2021 Mar; 59(3):189-194. PubMed ID: 33657692
    [No Abstract]   [Full Text] [Related]  

  • 54. Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
    Del Rizzo M; Fanin M; Cerutti A; Cazzorla C; Milanesi O; Nascimbeni AC; Angelini C; Giordano L; Bordugo A; Burlina AB
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S389-93. PubMed ID: 20830524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential patient screening for late-onset Pompe disease in suspected sleep apnea: a rationale and study design for a Prospective Multicenter Observational Cohort Study in Japan (PSSAP-J Study).
    Yamauchi M; Nakayama H; Shiota S; Ohshima Y; Terada J; Nishijima T; Kosuga M; Kitamura T; Tachibana N; Oguri T; Shirahama R; Aoki Y; Ishigaki K; Sugie K; Yagi T; Muraki H; Fujita Y; Takatani T; Muro S
    Sleep Breath; 2021 Jun; 25(2):695-704. PubMed ID: 32808237
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multisystem presentation of Late Onset Pompe Disease: what every consulting neurologist should know.
    Jastrzębska A; Kostera-Pruszczyk A
    Neurol Neurochir Pol; 2023; 57(2):143-150. PubMed ID: 36478346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutational spectrum and genotype-phenotype correlation in Mexican patients with infantile-onset and late-onset Pompe disease.
    Martinez-Montoya V; Sánchez-Sánchez LM; Sandoval-Pacheco R; Castro DMA; Arellano-Valdez CA; Ávila-Rejón CA; Aguilar-Juárez PA; Espino-Pluma M; González-Santillanes CA; Martínez-Segovia RI; Olmos-Morfin D; la Torre OP; Solís-Sánchez I; Espinosa MVM; Villarroel-Cortés CE; Velarde-Félix JS; López-Valdez J; Olaiz-Urbina J; Ricárdez-Marcial E; Vergara-Sánchez I; Radillo-Díaz P; Kazakova E; De la Fuente-Cortez B; Del Carmen Marquez-Quiróz L; Torres-Octavo B; Diaz-Martinez R
    Mol Genet Genomic Med; 2024 Jul; 12(7):e2480. PubMed ID: 38958145
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Newborn screening for Pompe disease: an update, 2011.
    Burton BK
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):8-12. PubMed ID: 22253219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: A multicenter study.
    Ünver O; Hacıfazlıoğlu NE; Karatoprak E; Güneş AS; Sağer G; Kutlubay B; Sözen G; Saltık S; Yılmaz K; Kara B; Türkdoğan D
    Neuromuscul Disord; 2016 Nov; 26(11):796-800. PubMed ID: 27666774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.